Anti-Human Podoplanin PE

Description: Podoplanin is a 40-kDa type I transmembrane sialomucin-like glycoprotein involved in platelet aggregation and cancer metastasis. This protein is expressed on lymphatic endothelial cells and follicular dendritic cells, as well as on many human cancers, including squamous cell carcinoma, glioblastoma, seminoma, and mesothelioma. Podoplanin expression has been demonstrated to be regulated by the Fos protein of the Activating Protein-1 (AP-1) transcription factor complex. Much of its functionality arises via interaction with its endogenous receptor, C-type lectin-like receptor-2 (CLEC-2).

This antibody has been reported to block the interaction between Podoplanin and CLEC-2.

References: Xie Q, Chen L, Fu K, Harter J, Young KH, Sunkara J, Novak D, Villanueva-Siles E, Ratech H. Podoplanin (d2-40): a new immunohistochemical marker for reactive follicular dendritic cells and follicular dendritic cell sarcomas.

Ogasawara S, Kaneko MK, Price JE, Kato Y. Characterization of anti-podoplanin monoclonal antibodies: critical epitopes for neutralizing the interaction between podoplanin and CLEC-2. Hybridoma (Larchmt). 2008 Aug;27(4):323. (NZ-1.3, WB, FC, Pubmed)

Durchdewald M, Guinea-Viniegra J, Haag D, Riehl A, Lichter P, Hahn M, Wagner EF, Angel P, Hess J. Podoplanin is a novel fos target gene in skin carcinogenesis. Cancer Res. 2008 Sep 1;68(17):6877-83.